- Home
- TNXP vs KZIA Comparison
TNXP vs KZIA Comparison
Compare TNXP & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TNXP | KZIA |
|---|---|---|
| Founded | 2007 | 1994 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 194.9M | 161.5M |
| IPO Year | N/A | 1999 |
Fundamental Metrics
Financial Performance| Metric | TNXP | KZIA |
|---|---|---|
| Price | $16.60 | $5.44 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $70.00 | $17.67 |
| AVG Volume (30 Days) | ★ 531.2K | 233.9K |
| Earning Date | 11-10-2025 | 12-26-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $10,299,000.00 | $1,199,108.00 |
| Revenue This Year | $2.96 | N/A |
| Revenue Next Year | $750.19 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.76 | $2.86 |
| 52 Week High | $69.97 | $17.40 |
Technical Indicators
Market Signals| Indicator | TNXP | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 44.02 | 35.44 |
| Support Level | $15.47 | $6.05 |
| Resistance Level | $17.52 | $11.06 |
| Average True Range (ATR) | 1.01 | 1.67 |
| MACD | -0.19 | -0.66 |
| Stochastic Oscillator | 22.20 | 0.00 |
Price Performance
Historical ComparisonAbout TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.